CTOs on the Move

Synaptogenix

www.synaptogen.com

 
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synaptogen.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 973.242.0005

Executives

Name Title Contact Details

Funding

Synaptogenix raised $14M on 01/21/2021
Synaptogenix raised $12.5M on 06/14/2021

Similar Companies

Ventus Therapeutics

Ventus is a newly established venture-backed biotech company pursuing small molecule therapeutics targeting key innate immune pathways for numerous auto-immune and auto-inflammatory diseases.

BioClin Therapeutics Inc

BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.

CARIS MPI

CARIS MPI is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zosano Pharma Inc

Zosano Pharma Inc is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kineta Pharmaceuticals

Kineta Pharmaceuticals is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.